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The Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) is
expressed in multiple human malignancies and has potent effects
on cell growth. It has been detected in exosomes and shown to
inhibit immune function. Exosomes are small secreted cellular
vesicles that contain proteins, mRNAs, and microRNAs (miRNAs).
Whenproduced bymalignant cells, they can promote angiogenesis,
cell proliferation, tumor-cell invasion, and immune evasion. In this
study, exosomes released from nasopharyngeal carcinoma (NPC)
cells harboring latent EBV were shown to contain LMP1, signal
transduction molecules, and virus-encoded miRNAs. Exposure to
theseNPC exosomes activated the ERK andAKT signaling pathways
in the recipient cells. Interestingly, NPC exosomes also contained
viral miRNAs, several of which were enriched in comparison with
their intracellular levels. LMP1 induces expression of the EGF recep-
tor in an EBV-negative epithelial cell line, and exosomes produced
by these cells also contain high levels of EGF receptor in exosomes.
These findings suggest that the effects of EBV and LMP1 on cellular
expression also modulate exosome content and properties. The
exosomes may manipulate the tumor microenvironment to influ-
ence the growth of neighboring cells through the intercellular
transfer of LMP1, signaling molecules, and viral miRNAs.
oncogene | herpesvirus
The Epstein–Barr virus (EBV) is a major human pathogen thatpotently affects cell growth regulation and is linked to the de-
velopment of multiple malignancies (1). These cancers contain the
viral genome but have different patterns of viral gene expression.
Latent membrane protein 1 (LMP1) is considered the major on-
cogene of EBV because it has transforming properties in cultured
cell lines, is essential for B-lymphocyte transformation, and is fre-
quently expressed in EBV-associated cancers (2, 3). LMP1 func-
tions as a constitutively active member of the tumor necrosis
factor receptor family and activates multiple signaling pathways,
including mitogen-activated protein kinase (MAPK), c-Jun N-
terminal kinase (JNK), phosphatidylinositol 3-kinase (PI3K)/Akt,
and NF-κB (4). LMP1 induces the expression of specific genes that
are involved with apoptosis, cell-cycle progression, cell prolif-
eration, and migration (4). One important target of LMP1 is epi-
dermal growth factor receptor (EGFR), a member of the ErbB
receptor tyrosine kinase family (5). Similarly to LMP1, EGFR
activates multiple signaling pathways, including Src kinases, JAKs/
STATs,Ras/MAPK, andPI3K/Akt (6). As a potent growth-signaling
receptor, theEGFRpathway is targetedby several oncogenic viruses,
including EBV, to affect cell growth (6). EBV-positive nasopharyn-
geal carcinoma (NPC) has elevated amounts of EGFR that are di-
rectly related to the expression level of LMP1 (5). EGFR can be
secreted from cells in exosomes and other microvesicles, and its
subsequent uptake by endothelial cells can induce tubule formation,
activation of MAPK and Akt pathways, and VEGF expression (7).
Interestingly, glioblastoma microvesicles contain a truncated onco-
genic form of EGFR that induces proliferation of a human glioma
cell line, suggestingpotential autocrine andparacrine stimulation (8).
Exosomes are 40- to 100-nm endosomal-derived vesicles that
are secreted from many cell types and transfer proteins, mRNAs,
and microRNAs (miRNAs) to neighboring or distant cells to
modulate immune function, angiogenesis, cell proliferation, tumor-
cell invasion, and cell-to-cell communication (9, 10). Exosomes are
present in many biological fluids, including the cerebrospinal fluid,
blood, andurine, and they likely affect physiologic processes (9, 10).
Exosomes are a recently discovered mechanism through which
cancer cells and virally infected cells can manipulate their micro-
environment. Viruses can use the exosome pathway for virus egress
and immune evasion (11–13). Interestingly, EBV-infected cells
release exosomes containing LMP1 that induce T-cell anergy (14).
LMP1 also increases the concentration and release of FGF-2,
a potent angiogenic factor, into exosomes (15).
In this study, the effects of LMP1 on exosome composition
and biochemical properties were evaluated. The data indicate
that LMP1 increases the release of EGFR into exosomes and
that purified exosomes containing LMP1 and EGFR are taken
up by epithelial, endothelial, and fibroblast cells, leading to the
activation of ERK and PI3K/Akt pathways. It has recently been
shown that cellular miRNAs are present in tumor-derived exo-
somes, and EBV miRNAs have also been detected in exosomes.
Similarly, data presented here show that an EBV-positive NPC
cell line produces exosomes that contain virus-encoded miRNAs
with differing relative abundances in comparison with their in-
tracellular levels in equal amounts of exosomal and intracellular
RNA, suggesting that some of the viral miRNAs may be selec-
tively packaged into exosomes. These findings suggest that EBV
utilizes the exosomal system to secrete key signaling molecules
and viral-encoded proteins and miRNAs. The effects of EBV
and LMP1 on exosomes are likely to be important factors in
EBV infection through which a small number of cells expressing
LMP1 could both modulate the tumor microenvironment and
also potentially impact the infected host.
Results
EBV-Infected NPC Produce Exosomes That Activate Growth-Signaling
Pathways. Exosomes containing LMP1 have been detected in the
serum of NPC patients, and NPC serum has been shown to have
mitogenic activity as measured by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (16). To evaluate
the properties of exosomes produced by NPC cells, exosomes
were harvested from the media of the NPC C666 cell line, an
NPC cell line that has retained EBV but expresses low to un-
detectable levels of LMP1 (17). Exosomes prepared from the
C666 cells and a derivative that stably expresses LMP1 (C666-
LMP1) or the pBabe vector control contained standard exosomal
markers HSC70 and flotillin-2 (Fig. 1A). LMP1 was abundant in
exosomes produced by C666-LMP1 but not detectable in exo-
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somes from theC666 vector control parental line. BothEGFRand
PI3K were detected in C666 and C666-LMP1 exosomes (Fig. 1A).
To evaluate the relative levels of LMP1 expression within cells
and exosomes, C666-LMP1 was compared with the prototype
EBV-transformed lymphoid cell line, B958 (Fig. 1B). LMP1
expression was equivalent in cell lysates of B958 and C666-LMP1
and was abundant within the exosomes produced by these cell
lines. LMP1 was also detected in exosomes produced by the C33
epithelial cell line stably expressing LMP1. The C15 NPC tumor
is a well-studied model of NPC that must be maintained as a xe-
nograft. The C15 cells can be viably maintained in culture for
brief time periods and have been shown to produce exosomes that
contain LMP1 and high levels of galectin 9 (13). LMP1 was
abundant in exosomes purified from the culture supernatants of
both C666-LMP1 and C15 (Fig. 1C). Importantly, LMP1 was also
detected in exosomes purified from the serum of mice carrying
the C15 tumor (Fig. 1C, serum), consistent with previous work on
NPC patient serum (16).
Recent studies have shown that tumor-derived exosomes can
be taken up by human umbilical vein endothelial cells (HUVECs).
The potential for internalization of NPC exosomes by this im-
portant cell type was evaluated by using C666 and C666-LMP1
exosomes produced by equivalent cell numbers that were purified,
fluorescently labeled, and incubated with HUVECs for various
times. The cells were extensively washed, and binding was evalu-
ated as a percentage of the total fluorescence for each sam-
ple added to the cells. Within 30 min, 20% of the parental C666
exosomes and ≈40% of C666-LMP1 exosomes bound to
HUVECs, and, after 17-h incubation, binding increased to 60%
and 80%, respectively (Fig. 1D). LMP1 modulates the levels of
many proteins involved in adhesion and cellular interaction, which
could contribute to the potential increased binding efficiency of
the LMP1 exosomes. Confocal microscopy of the HUVECs
treated with fluorescently labeled exosomes for 16 h revealed
punctuate internal staining, suggesting that the exosomes were
taken up into endocytic compartments (Fig. 1E). After extensive
washing, fluorescence was only detected in confluent monolayers
of HUVECs incubated with 1,1′-dioctadecyl-3,3,3′3′-tetramethy-
lindocarbocyanine perchlorate (DiI)- labeled C666 exosomes but
not with media containing dye without exosomes, indicating that
Fig. 1. Characterization of NPC exosomes and
their uptake by HUVECs. (A) Purified exosomes
from conditioned media of C666-pBabe and
C666-LMP1 were analyzed by immunoblotting
with the indicated antibodies and the LMP1 S12
monoclonal antibody. (B) Levels of LMP1 within
cellular lysates were compared between C666-
LMP1 and B958 cells and in exosomes produced
by C666-LMP1, B958, and C33A-LMP1. (C) Exo-
somes from cultured C666 cells, C15 xenograft,
or C15 mouse serum were analyzed by immu-
noblotting for LMP1 levelsbyusingpooledLMP1
rat monoclonal antibodies. (D and E) Three sep-
arate preparations of purified exosomes were
labeled with DiI and incubated with HUVECs for
the indicated times. Fluorescencewasmonitored
in a plate reader (D) or by confocal microscopy
(E). The numbers were normalized to equal DiI
totals and represented as a percentage of exo-
somes adhered. (F and G) Annexin blocking of
exosome fusion was measured by fluorescence
dequenching of R18-labeled exosomes at the
indicated times by using a plate reader (F) or vi-
sualized by confocal microscopy (G).








cell membranes did not nonspecifically take up contaminating dye
(Fig. 1E Left).
It has been shown that exosomes contain exposed phosphati-
dyl serine and their fusion with target cell membranes can be
inhibited with annexin V (18). To assess the requirement for
exosomal fusion, a fusion assay was performed with the R18 self-
quenching dye. Detection of fluorescence reflects dequenching of
the dye and is indicative of fusion with the unlabeled cellular
membrane. This fluorescence is then compared with the total
fluorescence in the sample determined by dequenching with de-
tergent treatment. Fluorescence indicative of fusion was readily
detected in HUVECs incubated with R18-labeled C666 exosomes
such that 20% of the exosomal membranes had fused in 30 min
(Fig. 1F). Preincubation of labeled exosomes with annexin V,
a phosphatidyl serine-binding protein, decreased the total amount
of fluorescence detected at each time point with an overall de-
crease of ≈50% (Fig. 1F). This effective blocking is comparable to
previous studies and confirms that the NPC exosomes fuse with
cellular membranes (7). Confocal microscopy of HUVECs ex-
posed to annexin V-treated and untreated exosomes also con-
firmed exosomal uptake into punctuate vesicles and indicated that
this uptake was specifically blocked by annexin (Fig. 1G).
LMP1 activates multiple cellular signaling pathways, and
the activation of PI3K, Akt, and ERK are essential for LMP1-
mediated transformation of fibroblasts. To assess the potential
transfer of LMP1 as well as the activation of ERK and Akt,
HUVECs were cultured in serum-free conditions and exposed to
increasing amounts of purified C666-LMP1 exosomes for 24 h.
Detection of LMP1 in cell lysates, as determined by immuno-
blotting, was dose-dependent. Additionally, activated phosphory-
lated ERK was detected and was also proportional to the exosome
concentration from both C666-pBabe and C666-LMP1 cells (Fig.
2). To determine whether LMP1 modulates the ability to activate
signaling pathways in recipient cells, duplicate cultures ofHUVECs
were exposed to equivalent amounts of exosomes from C666-
pBabe or C666-LMP1 and analyzed for AKT and ERK activation.
Although C666-pBabe exosomes were capable of activating these
pathways, C666-LMP1 exosomes induced consistently higher levels
of activation (Fig. 2C). These findings suggest that NPC exosomes
stimulate growth-signaling pathways and that LMP1 can enhance
these effects. Importantly, HUVECs are a highly significant cell
type whose growth and activation would be important for tumor
growth with enhanced vascularization and metastasis.
Properties of Exosomes Released from LMP1-Expressing Cells. In
C33A epithelial cells, LMP1 greatly increases expression of
EGFR. To assess the effects of LMP1 on exosomes produced by
these cells, exosomes were purified from the media of C33A cells
stably expressing LMP1 or vector control by sequential centrifu-
gation. Equivalent total protein levels from the pelleted material
were subsequently analyzed for specific exosomal components
and signaling molecules. The exosomal components HSC70 and
flotillin-2 were detected in exosome preparations from LMP1-
expressing and vector control cells (Fig. 3A) (15, 19). The endo-
plasmic reticulum-localized protein GRP78 was not detected,
indicating that the preparations were not contaminated with ap-
optotic bodies, which contain high levels of endoplasmic re-
ticulum-derived proteins. The purified LMP1-C33A exosomes
contained abundant LMP1 and high levels of EGFR (Fig. 3A).
PI3K is an important intracellular signal transducer that can bind
LMP1 and EGFR and is constitutively activated by LMP1 or EGF
treatment. Immunoblotting for p85, the PI3K regulatory subunit,
detected the protein in both the pBabe vector control and LMP1-
C33A exosome preparations at approximately equivalent levels.
Thus, exosomes can contain LMP1, EGFR, and their specific
signal transducers.
Purified C33A exosomes were incubated with C33A parental
cells for 24 h in serum-free media. After incubation, LMP1 was
detected in the lysates of recipient cells with an LMP1-specific
antibody (S12) (Fig. 3B). Immunoblots of cells exposed to LMP1
exosomes compared with the control exosomes indicated slightly
increased levels of phosphorylated ERK and Akt with LMP1
(Fig. 3B). The modest, yet reproducible, activation of these
pathways in the C33A cells exposed to LMP1-containing exo-
somes likely reflects the elevated endogenous levels of activity in
this highly transformed cancer cell line.
Transformation of Rat1 cells by LMP1 requires activation of
PI3K and ERK (20). To determine the effects of C33A exosomes
in untransformed cells, Rat-1 fibroblasts were exposed to purified
LMP1 exosomes, control exosomes, or PBS. Rat-1 cells exposed to
LMP1-containing exosomes had elevated levels of phosphorylated
ERK and Akt compared with control exosomes or PBS alone.
However, the activation of these pathways in Rat-1 cells was not
Fig. 2. Transfer of LMP1 and activation of ERK and AKT pathways in HUVECs by NPC exosomes. HUVECs were incubated with increasing amounts of purified
C666-LMP1 (A) or C666-pBabe (B) exosomes for 24 h in serum-free media. Cell lysates were analyzed by immunoblotting for the indicated proteins and S12
mAb for LMP1. (C) HUVECs exposed to 400 μg of pBabe or LMP1 exosomes for 24 h were analyzed by immunoblotting for activated ERK and AKT. Levels of
pAKT and pERK normalized to total AKT and ERK protein levels and represented relative to pBabe exosomes are shown from three independent experiments.
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readily detectable until 72 h (Fig. 3C). This delayed activation may
reflect differences in the rate of uptake between cell lines.
It is likely that the multiple centrifugation and pelleting steps in
exosomal purification damage exosomes and impair their uptake
or function. To evaluate this possibility, Rat-1 cells were exposed
to C33A-conditioned media, clarified from cell debris, every 24 h
for 5 d. Immunoblot analysis detected LMP1 and activated Akt
and ERK in the Rat-1 recipient cell lysates exposed to the media
from LMP1-C33A cells but not from the pBabe vector control
cells or fresh DMEM (Fig. 3D). These data indicate that both
purified LMP1-containing exosomes or conditioned media con-
taining LMP1 exosomes can transfer LMP1 and activate ERK
and Akt in the recipient cells.
To evaluate the effects of LMP1- and EGFR-containing C33A
exosomes on HUVECs and confirm the results obtained with
NPC exosomes, cells were exposed to purified C33A exosomes or
PBS as described in Materials and Methods. LMP1 was detected
by immunoblotting in lysates of HUVEC cells exposed to LMP1-
containing exosomes by 6 h posttransfer (Fig. 4A). Activated
phosphorylated ERK and Akt were detected in the lysates of
HUVEC cells exposed to LMP1-containing exosomes (Fig. 4B)
with an average fold increase over pBabe exosomes of 2.0 ± 0.7
for phosphorylated AKT (pAKT) and 2.5 ± 0.9 for phosphory-
lated ERK (pERK). These data indicate LMP1 can be effectively
transferred to endothelial cells through exosomes and can acti-
vate the MAPK and Akt pathways.
Exosomes Released from EBV-Positive NPC Cells Contain Virus-
Encoded miRNAs. It has been shown that exosomes contain both
cellular mRNA and miRNA that can be transferred to other cells
to impact cell growth through effects on new protein synthesis or
translational inhibition of specific proteins (8, 21). A recent study
showed that EBV-infected lymphocytes produced exosomes that
contain viral miRNAs and that these miRNAs could be trans-
ferred and decrease levels of known cellular targets (22). The
majority of the EBV miRNAs are produced from the BART
viral transcripts that were initially identified in NPC and are
expressed at high levels in NPC and gastric cancer but at low
levels in most lymphocyte cell lines or lymphomas (23, 24). To
evaluate the incorporation of the viral BART miRNAs in exo-
somes secreted from EBV-positive NPC, exosomes were purified
from the media of C666 cells and the total RNA was extracted
from the exosome pellet. An equal amount of total RNA from
exosomes and cells was analyzed by using quantitative RT-PCR
with primers specific for EBV miRNAs. Comparing the amount
of individual EBV exosomal miRNAs to the intracellular levels
of the specific viral miRNAs revealed differences in the relative
levels, which may indicate that their presence in exosomes is not
a random event (Fig. 5A). In addition, the amount of enrichment
differed between the individual miRNAs, suggesting that some
viral miRNAs may be selectively transported to exosomes. The
small nuclear RNA U5 was used as an internal negative control
and was not enriched in the exosome preparations. Northern blot
analysis for BART 7 using equal amounts of total cellular RNA
from C666 cells, the EBV-positive NPC xenograft, C15, and the
EBV-negative BCBL1 lymphoma compared with RNA from
C666 exosomes indicated that the exosomes contain the pro-
cessed BART 7 miRNA at levels comparable to NPC tumors
that express high levels of the BART miRNAs (Fig. 5B).
To determine whether viral miRNAcould be transferred to cells
not harboring EBV, HUVEC cells were exposed to increasing
Fig. 3. Exosomes and conditioned media from LMP1-expressing C33A cells
activate ERK and AKT in recipient cells. (A) Cell lysates and purified exosomes
from C33A-LMP1 or C33A-pBabe cells were analyzed by immunoblotting
with antibodies against EGFR, p85, GRP78, HSC70, LMP1, flotillin-2, actin,
and S12 mAb for LMP1. (B) Untransfected C33A cells were incubated with
C33A-pBabe or LMP1 exosomes for 24 h in serum-free media, and the in-
dicated proteins were identified by immunoblotting of cell lysates. (C) C33A
exosomes were incubated with Rat-1 cells for 72 or 96 h, and cell lysates
were analyzed for the indicated proteins by immunoblotting. Numbers in-
dicate fold change over PBS control. (D) Media alone (DMEM) or conditioned
media from C33A-pBabe or C33A-LMP1 was clarified and added to Rat-1
cells every 24 h for 5 d. pAKT and pERK intensities in all experiments were
normalized to total protein levels, and the relative values to the control are
indicated in each channel. Representative blots from two to four in-
dependent experiments are shown.
Fig. 4. Activation of ERK andAKTpathways in HUVECs exposed toC33A-LMP1
exosomes.HUVECswere incubatedfor6hwithPBS,pBabe,andLMP1exosomes,
and recipient cell lysates were immunoblotted for LMP1 with the S12 mono-
clonal antibody (A) or pAKT and pERK (B) withAKT and ERK as loading controls.
Representative results from three independent experiments are shown.








amounts of C666 exosomes for 6 h, extensively washed, and then
the RNA was analyzed by RT-PCR for the presence of three dif-
ferentEBVmiRNAs. TheEBVmiRNAswere detected in the total
RNA isolated fromHUVECs exposed toC666 exosomes in a dose-
dependent manner (Fig. 5C). These data indicate that viral miR-
NAs may be packaged into exosomes for transfer to other cells,
which likely provides the virus a unique mechanism for epigenetic
effects in neighboring cells. It is possible that the potential selective
packaging of individual miRNAs is linked to targeting of specific
proteins within the recipient cells.
Discussion
The data presented here reveal that, through exosomal secretion
and uptake, a human tumor virus can induce the transfer of a viral
oncoprotein, signal transduction molecules, and virus-encoded
miRNAs into multiple cell types and activate cell-signaling path-
ways. These findings suggest that through exosomes EBV could
manipulate the tumor microenvironment to enhance tumor pro-
gression. LMP1 is not always detected within every tumor cell or
sample. However, the exosomal transfer of LMP1 and other sig-
naling molecules could impact growth control of other cells within
a tumor. Immune detection would also be impaired by this limited
expression within a rare cell. The data described here clearly show
that LMP1 can be transferred to cells through exosomes and that
NPC exosomes can activate growth-signaling pathways.
It is presently unknown how the levels of exosomes used in these
studies compare with the in vivo situation as the concentration of
exosomes and transfer efficiency are likely to be much greater at
the cell–cell interface, perhaps similar to what has been described
for the transfer of components between neurons and immune cells
(25). The ability to detect LMP1 in the exosome pellet harvested
from serum of mice carrying the C15 tumor supports a physio-
logical role of LMP1-containing exosomes in NPC.
The data presented here indicate that LMP1 is efficiently
transported into exosomes and likely affects the components of
exosomes, perhaps indirectly, through its effects on cellular ex-
pression. The biogenesis of exosomes is linked to both multi-
vesicular bodies and lipid rafts (26, 27). Protein sorting into
multivesicular bodies is thought to involve monoubiquitination of
cargo proteins for entry into the endosomal sorting complex.
LMP1 is ubiquitinated and has been detected in multivesicular
bodies (15, 28). Protein targeting into exosomes also involves lipid
raftmicrodomains, and purified exosomalmembrane components
are enriched with molecules that are characteristic of lipid rafts,
including sphingomyelin, cholesterol, and the glycolipid GM3 (27,
29). Thus, the partitioning of some proteins to lipid rafts likely
contributes to exosome targeting. LMP1 localizes to lipid raft
microdomains, and this localization is critical for LMP1-mediated
signaling events (30, 31). The findings presented here indicate that
LMP1 is enriched in exosomes and that exosomes also contain
signaling proteins such as EGFR and PI3K through which LMP1
affects cell growth.
This study also reveals that the exosomes produced by LMP1-
expressing epithelial cells can be taken up by fibroblast, epithe-
lial, and endothelial cells. It is presently unclear exactly how
exosomes contact and enter cells and, similarly to viruses, may
have diverse entry pathways (32). The confocal images confirm
that C666 exosomes both bind and are internalized by endo-
thelial cells, and the punctate internal staining is similar to endo-
cytic uptake of exosomes. An additional property of the LMP1-
containing exosomes is their potential enhanced binding to
HUVECs. LMP1 affects the expression of multiple cellular pro-
teins that are involved in adhesion and cell communication. The
further analysis of the exosomal components modulated by LMP1
may likely identify proteins that are increased within exosomes
and facilitate binding and entry.
A recent study showed that EBV-transformed lymphocytes
produced exosomes that contained EBV miRNAs and that these
miRNAs could modulate their known targets within the recipient
cell (22). The findings in this study reveal that the EBV BART
miRNAs that are most abundant in NPC and other epithelial
tumors are also present within exosomes produced from infected
epithelial cells. Of particular interest is the possibility that certain
viral miRNAs are detected at higher relative levels within exo-
somes than within the cell, possibly reflecting preferential sorting
into exosomes. Perhaps a subset of the viral miRNAs specifically
functions in cells other than those producing them. A recent study
demonstrated that components of the miRNA effector complexes
associate with multivesicular bodies and are secreted into exo-
somes (33). One component, GW182, that is required for miRNA
function through its association with argonaute 2 (AGO2) was
dramatically enriched in exosomes. These findings suggest that
exosomes may not only transfer viral miRNAs but also deliver
cellular components of the RNA-induced silencing complex to
enhance their function.
This study indicates that LMP1, and possibly other viral proteins,
may have potent effects on exosome components and functions. It
is likely that other viruses that establish long-term, latent, or chronic
infections also modulate exosomes to enhance their persistence.
The further understanding of how viruses modulate exosome pro-
duction and function will likely clarify their biogenesis and the
Fig. 5. ViralmiRNAsare enriched inNPCexosomes and takenupbyHUVECs. (A) Total RNAfromC666 cells or exosomeswas analyzedbyusingquantitativeRT-PCR
for theBARTmiRNAswith the small nuclearRNAU5Aasanegative control.Dataare representedas relative levels of the individualmiRNAs in comparisonwith their
intracellular levels in equal amounts of C666 total cell RNAand exosomal RNA from three independent experiments run in triplicate. (B) Equal amounts of total cell
RNA from C666 cells or three independent exosome preps were separated in tris-borate-EDTA gels and transferred to HybondN+, hybridized with an end-labeled
anti-senseoligo to themiRNA-Bart7, and visualizedby autoradiography. EBV-negative BCBL1 cellswereused as a negative control, and theC15xenograftwas used
as a positive control. (C) HUVEC cells were exposed to C666 exosomes for 6 h, andmiRNAuptakewasmonitored by quantitative RT-PCR of total RNA isolated from
HUVECs that hadbeenextensivelywashed to removeunbound exosomes.miRNA levels are represented as relative to theamountof eachmiRNApresentwithin an
equivalent amount of C666 cellular RNA.
20374 | www.pnas.org/cgi/doi/10.1073/pnas.1014194107 Meckes et al.
mechanisms through which exosomes affect intercellular commu-
nication and potentially enable persistent infection.
Materials and Methods
Cell Culture. C33A cervical carcinoma cells that express pBabe (vector), or
pBabe-HA-LMP1 have been described previously (34). C666-1 cells and those
stably expressing HA-LMP1 were produced by retrovirus transduction as de-
scribed (35). HUVECswere cultured in endothelial cell growthmedia-2 (Lonza)
supplemented with the supplied growth factors, 12% FBS, and antibiotic/
antimycotic. All cells were maintained at 37 °C with 5% CO2. The C15 xeno-
graft tumor was cultured in vitro for 2 d as previously described (12).
Antibodies. Antibodies were purchased as indicated: pAkt (Ser473) and anti-
Akt (Cell Signaling); anti-GRP78, anti-HSC70, anti-actin, anti-pERK, total ERK,
anti-GAPDH, andanti-TSG101 (SantaCruzBiotechnology); anti-PI3K (Upstate);
and anti–flotillin-2 (BD Biosciences). S12 anti-LMP1 was obtained from
supernatants of the hybridoma produced by David A. Thorley-Lawson (Tufts
University). The pooled anti-LMP1 rat monoclonal antibodies (1G6, 7G8, and
7E10) were obtained from Ascenion.
Exosome Isolation and Transfer. Confluent monolayers were grown to 1 d
postconfluency. Exosomes were collected by differential centrifugation from
conditioned media or C15 serum, resuspended into PBS, and stored at −80 °C
until use (36). Cell monolayers were washed twice with PBS and incubated
with purified exosomes (200–400 μg) or PBS for the indicated times at 37 °C in
serum-free media. Cells exposed to exosomes were washed three times with
PBS, scraped into cold PBS, pelleted, and lysed in radioimmunoprecipitation
assay (RIPA) buffer (20). Subconfluent Rat-1 cells were exposed to condi-
tioned, clarified media from C33A cells every 24 h for 5 d.
DiI-Labeled Exosomes to HUVECs. C666-1 cells were grown in exosome-free
media for 5 d. Purified exosomes from equivalent cell numbers were labeled
with 1 μMDiI (Invitrogen) or 1mMR18 (Invitrogen) as previously described (37).
Pelletedexosomeswerewashed to removeunboundDiI andwere resuspended
in PBS/5% BSA. Exosomes from equivalent numbers of cells were exposed to
HUVECs. Recipient cells were then washed in PBS, fixed in 4% para-
formaldehyde, and imaged by confocal microscopy (Olympus FV500), or for
adhesion assaysfluorescencewas determined by using a plate readerwith 544/
590-nm Ex/Em filters. To correct for potential differences between exosome
concentration or labeling, the percentage of exosomes adhered was calculated
from the total DiI fluorescence of the individual washed and pelleted samples.
SDs were calculated from triplicate wells exposed to three separate prepara-
tions of exosomes. For annexin V blocking, R18-labeled exosomes were pre-
incubated with 2 μg/mL annexin V (BD Biosciences) before addition to HUVECs,
and SEMwas calculated from triplicate wells of two independent experiments.
RNA Preparations and RT-PCR. Total RNA fromcell pellets or exosomepellets of
the C666-1 cell line was prepared with TRIzol reagent (Invitrogen) per man-
ufacturer’s directions. Quantitative RT-PCR was performed for the BART
miRNAs from equal amounts of total C666 exosome and cellular RNA by using
the miScript system (Qiagen) with SYBR green dye. Relative abundance of
miRNAs was determined by subtracting the cycle threshold of the cellular
miRNAs from the exosomal miRNAs to the log base 2. The small nuclear RNA
U5 was included as a control.
Northern Blotting. Northern blots for miRNAs were prepared by using precast
15% urea tris-borate-EDTA gels (Bio-Rad) and transferred to Hybond N+ (GE
Biosciences) (38). After UV cross-linking, the membranes were hybridized at
37 °C with an end-labeled anti-sense oligo to the miR-Bart7 by using Expres-
sHyb solution (Clontech) as directed. Total RNA from the BCBL1 cell line and
the C15 xenograft were used as negative and positive controls.
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